EU/3/13/1102: Orphan designation for the treatment of high-altitude pulmonary oedema



On 8 February 2013, orphan designation (EU/3/13/1102) was granted by the European Commission to Apeptico Forschung und Entwicklung GmbH, Austria, for Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys for the treatment of high-altitude pulmonary oedema.

Key facts

Active substance
Intended use
Treatment of high-altitude pulmonary oedema
Orphan designation status
EU designation number
Date of designation
Apeptico Forschung und Entwicklung GmbH
MariahilferStraße 136, Top 1.15
1150 Vienna
Tel. +43 664 1432 919
Fax +43 125 3303 37795

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating